StatPearls

Related Articles

StatPearls

Book. 2017 06

Authors:

Abstract
Desipramine is a secondary amine tricyclic antidepressant that is FDA approved for the treatment of depression. It is not considered the first line for depression due to the several adverse effects of this drug. This drug has been used off-label to treat bulimia nervosa, irritable bowel syndrome, neuropathic pain, overactive bladder, post-herpetic neuralgia, and ADHD. Efficacy of desipramine can be established within the first 2 weeks of treatment of bulimia nervosa patients. This was established by a study of 77 patients plotted on a receiver operating character curve examining the relationship between time and symptom reduction. Alleviation of symptoms in irritable bowel syndrome and neuropathic pain is accomplished by the antinociceptive properties of Desipramine. Desipramine has been shown to have therapeutic antinociceptive benefits most likely via its influence of norepinephrine. In addition to patients with simple overactive bladder, desipramine was found useful in patients with complex overactive bladder caused by pelvic radiation and overactive bladder with pain. Desipramine has been established as one of the first-line drugs in treating postherpetic neuralgia, however, due to its toxic profile physicians are often inclined to use second-line medications such as gabapentin. Desipramine has shown mild effectiveness in the treatment ADHD.

PMID: 29262158

via https://www.ncbi.nlm.nih.gov/pubmed/29262158?dopt=Abstract